NDAOPHTHALMICSUSPENSION/DROPS
Approved
Jun 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
METIMYD is a fixed-dose ophthalmic suspension combining prednisolone acetate (a corticosteroid) and sulfacetamide sodium (a sulfonamide antibiotic) for topical ocular use. It treats bacterial conjunctivitis and other inflammatory ocular conditions where both anti-inflammatory and antimicrobial activity are needed. The corticosteroid reduces inflammation while the antibiotic addresses bacterial infection.
LOE Approaching
As LOE approaches with moderate competitive pressure (30), brand teams face declining market share and reduced headcount allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on METIMYD offers minimal career growth opportunity given its LOE-approaching status and zero linked job openings. This product is primarily suited for early-career professionals seeking experience in legacy brand management or those nearing transition roles.
Brand ManagerField Sales Representative
Worked on METIMYD at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.